NYSE:ZBH - Zimmer Biomet Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $152.57
  • Forecasted Upside: 1.70 %
  • Number of Analysts: 24
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 16 Buy Ratings
  • 2 Strong Buy Ratings
$150.02
▲ +0.34 (0.23%)
1 month | 3 months | 12 months
Get New Zimmer Biomet Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZBH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZBH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$152.57
▲ +1.70% Upside Potential
This price target is based on 24 analysts offering 12 month price targets for Zimmer Biomet in the last 3 months. The average price target is $152.57, with a high forecast of $177.00 and a low forecast of $106.00. The average price target represents a 1.70% upside from the last price of $150.02.
Buy
The current consensus among 24 investment analysts is to buy stock in Zimmer Biomet. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 2 strong buy ratings
  • 15 buy ratings
  • 5 hold ratings
  • 1 sell ratings
6/8/2019
  • 2 strong buy ratings
  • 13 buy ratings
  • 6 hold ratings
  • 1 sell ratings
9/6/2019
  • 2 strong buy ratings
  • 14 buy ratings
  • 6 hold ratings
  • 1 sell ratings
12/5/2019
  • 2 strong buy ratings
  • 18 buy ratings
  • 5 hold ratings
  • 1 sell ratings
3/4/2020
  • 2 strong buy ratings
  • 18 buy ratings
  • 6 hold ratings
  • 1 sell ratings
6/2/2020
  • 2 strong buy ratings
  • 16 buy ratings
  • 4 hold ratings
  • 1 sell ratings
8/31/2020
  • 2 strong buy ratings
  • 17 buy ratings
  • 5 hold ratings
  • 1 sell ratings
10/30/2020
  • 2 strong buy ratings
  • 16 buy ratings
  • 5 hold ratings
  • 1 sell ratings
11/29/2020

Latest Recommendations

  • 2 strong buy ratings
  • 16 buy ratings
  • 5 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2020OppenheimerBoost Price TargetOutperform$150.00 ➝ $155.00Medium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
11/9/2020Credit Suisse GroupBoost Price TargetUnderperform$99.00 ➝ $106.00High
i
Rating by Matt Miksic at Credit Suisse Group AG
11/9/2020SVB LeerinkBoost Price TargetOutperform$160.00 ➝ $167.00High
i
10/27/2020CowenBoost Price TargetPositive ➝ Market Perform$130.00 ➝ $150.00High
i
10/20/2020Northland SecuritiesInitiated CoverageMarket Perform$150.00Low
i
10/12/2020Raymond JamesBoost Price TargetStrong-Buy$150.00 ➝ $170.00Low
i
10/5/2020SVB LeerinkBoost Price TargetOutperform$153.00 ➝ $160.00Medium
i
9/11/2020Wolfe ResearchInitiated CoverageOutperform$174.00Low
i
9/4/2020ArgusBoost Price Target$145.00 ➝ $160.00Low
i
8/18/2020Morgan StanleyReiterated RatingBuy$150.00Medium
i
Rating by David Lewis at Morgan Stanley
8/5/2020Credit Suisse GroupReiterated RatingSell$99.00Low
i
Rating by Matt Miksic at Credit Suisse Group AG
8/5/2020Morgan StanleyBoost Price TargetOverweight$140.00 ➝ $150.00Low
i
8/5/2020OppenheimerBoost Price TargetOutperform$138.00 ➝ $150.00Medium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/5/2020SVB LeerinkBoost Price TargetOutperform$146.00 ➝ $153.00Medium
i
8/5/2020Raymond JamesBoost Price TargetStrong-Buy$140.00 ➝ $150.00Low
i
8/5/2020CitigroupBoost Price TargetBuy$140.00 ➝ $155.00Low
i
8/4/2020Needham & Company LLCInitiated CoverageStrong-Buy$148.00 ➝ $162.00Low
i
Rating by Michael Matson at Needham & Company LLC
8/4/2020BTIG ResearchReiterated RatingBuy$139.00Medium
i
8/4/2020OppenheimerReiterated RatingBuy$138.00Medium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
7/15/2020SVB LeerinkBoost Price TargetOutperform$136.00 ➝ $146.00High
i
5/28/2020OppenheimerInitiated CoverageBuy$138.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/18/2020JMP SecuritiesLower Price TargetPositive ➝ Outperform$175.00 ➝ $150.00High
i
5/12/2020Canaccord GenuityBoost Price TargetBuy$135.00 ➝ $137.00High
i
5/12/2020UBS GroupLower Price TargetBuy$180.00 ➝ $165.00High
i
5/12/2020Stifel NicolausBoost Price TargetBuy$111.00 ➝ $130.00High
i
5/12/2020SunTrust BanksBoost Price TargetBuy$125.00 ➝ $132.00High
i
5/12/2020Deutsche Bank AktiengesellschaftLower Price TargetHold$160.00 ➝ $146.00High
i
5/12/2020Wells Fargo & CompanyBoost Price TargetOverweight$124.00 ➝ $132.00High
i
5/12/2020SVB LeerinkBoost Price TargetOutperform$130.00 ➝ $136.00High
i
5/12/2020Raymond JamesBoost Price TargetStrong-Buy$136.00 ➝ $140.00High
i
Rating by Lawrence Keusch at Raymond James
5/12/2020CitigroupBoost Price TargetBuy$125.00 ➝ $140.00High
i
5/11/2020OppenheimerLower Price TargetOutperform$141.00 ➝ $138.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/11/2020Wells Fargo & CompanyReiterated RatingBuyHigh
i
5/11/2020Piper SandlerLower Price TargetIn-Line ➝ Overweight$175.00 ➝ $160.00High
i
5/11/2020Needham & Company LLCLower Price TargetStrong-Buy$153.00 ➝ $148.00Medium
i
4/28/2020OppenheimerLower Price TargetOutperform$175.00 ➝ $141.00Medium
i
4/28/2020GuggenheimDowngradeBuy ➝ NeutralMedium
i
4/19/2020Evercore ISIDowngradeOutperform ➝ In-LineMedium
i
4/13/2020Raymond JamesLower Price TargetStrong-Buy$190.00 ➝ $136.00Low
i
Rating by Lawrence Keusch at Raymond James
4/7/2020SVB LeerinkBoost Price TargetOutperform$121.00 ➝ $130.00High
i
4/7/2020SunTrust BanksLower Price TargetBuy$179.00 ➝ $125.00High
i
4/7/2020BTIG ResearchLower Price TargetBuy$170.00 ➝ $130.00Low
i
4/7/2020Needham & Company LLCLower Price TargetStrong-Buy$189.00 ➝ $153.00High
i
3/27/2020Morgan StanleyLower Price TargetOverweight$175.00 ➝ $140.00Low
i
3/27/2020CitigroupLower Price TargetBuy$168.00 ➝ $125.00High
i
3/25/2020SVB LeerinkLower Price TargetOutperform$181.00 ➝ $121.00High
i
3/24/2020Stifel NicolausLower Price TargetBuy$180.00 ➝ $93.00High
i
3/6/2020Credit Suisse GroupLower Price TargetOutperform$125.00 ➝ $115.00High
i
3/4/2020CitigroupInitiated CoverageBuy$168.00High
i
2/12/2020The Goldman Sachs GroupInitiated CoverageBuy$177.00Low
i
2/6/2020JMP SecuritiesReiterated RatingAverage ➝ Outperform$175.00Low
i
2/5/2020OppenheimerBoost Price Target$165.00 ➝ $175.00Low
i
2/5/2020Robert W. BairdBoost Price TargetOutperform$161.00 ➝ $172.00Low
i
2/5/2020Deutsche Bank AktiengesellschaftBoost Price TargetHold$144.00 ➝ $160.00Low
i
2/5/2020Credit Suisse GroupBoost Price TargetUnderperform$120.00 ➝ $125.00Low
i
2/5/2020BTIG ResearchReiterated RatingBuy$170.00Low
i
2/5/2020Morgan StanleyBoost Price TargetOverweight$170.00 ➝ $175.00Low
i
2/5/2020Raymond JamesBoost Price TargetPositive ➝ Strong-Buy$170.00 ➝ $190.00Low
i
Rating by Lawrence Keusch at Raymond James
2/4/2020Piper SandlerBoost Price TargetOverweight$170.00 ➝ $175.00Low
i
2/4/2020Needham & Company LLCReiterated RatingStrong-Buy$187.00 ➝ $189.00High
i
Rating by Michael Matson at Needham & Company LLC
1/10/2020Wells Fargo & CompanyBoost Price TargetOverweight$165.00 ➝ $170.00Medium
i
1/7/2020SunTrust BanksInitiated CoverageBuy$179.00Medium
i
1/7/2020Piper SandlerUpgradeNeutral ➝ Overweight$140.00 ➝ $170.00Low
i
1/7/2020Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$140.00 ➝ $170.00Low
i
1/3/2020Deutsche Bank AktiengesellschaftInitiated CoverageHold$108.00Low
i
1/2/2020CitigroupUpgradeNeutral ➝ BuyLow
i
12/19/2019Needham & Company LLCBoost Price TargetStrong-Buy$170.00 ➝ $187.00Low
i
Rating by Michael Matson at Needham & Company LLC
12/17/2019Morgan StanleyBoost Price TargetOverweight$150.00 ➝ $170.00Low
i
12/12/2019Wells Fargo & CompanyBoost Price TargetOverweight$158.00 ➝ $165.00Low
i
12/9/2019Wells Fargo & CompanyReiterated RatingBuyMedium
i
12/4/2019Raymond JamesUpgradeOutperform ➝ Strong-Buy$160.00 ➝ $170.00High
i
11/6/2019Royal Bank of CanadaBoost Price TargetOutperform$145.00 ➝ $155.00Low
i
11/6/2019Raymond JamesBoost Price TargetOutperform$150.00 ➝ $160.00Medium
i
11/6/2019SVB LeerinkBoost Price TargetOutperform$155.00 ➝ $160.00Medium
i
11/5/2019Needham & Company LLCReiterated RatingBuy$170.00Medium
i
Rating by Michael Matson at Needham & Company LLC
10/7/2019BTIG ResearchUpgradeNeutral ➝ Buy$158.00Low
i
9/23/2019CowenSet Price TargetBuy$140.00Medium
i
Rating by Josh Jennings at Cowen Inc
9/18/2019Needham & Company LLCReiterated RatingBuy$170.00Medium
i
9/18/2019Canaccord GenuityUpgradeHold ➝ Buy$137.00 ➝ $167.00Medium
i
9/17/2019Stifel NicolausSet Price TargetBuy$155.00Low
i
Rating by Rick Wise at Stifel Nicolaus
9/16/2019BTIG ResearchReiterated RatingHoldLow
i
9/9/2019Wells Fargo & CompanyBoost Price TargetOutperform$150.00 ➝ $158.00Medium
i
8/12/2019ArgusUpgradeHold ➝ Buy$160.00Low
i
8/2/2019CitigroupBoost Price TargetBuy$146.00 ➝ $158.00Low
i
7/30/2019BarclaysUpgradeUnderweight ➝ Equal Weight$117.00 ➝ $140.00Low
i
Rating by Kristen Stewart at Barclays PLC
7/29/2019OppenheimerBoost Price TargetOutperform$135.00 ➝ $150.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
7/29/2019Morgan StanleyBoost Price TargetOverweight$143.00 ➝ $150.00Low
i
7/29/2019Wells Fargo & CompanyBoost Price TargetOutperform$143.00 ➝ $150.00Low
i
7/29/2019Raymond JamesBoost Price TargetOutperform$145.00 ➝ $150.00Low
i
7/29/2019Credit Suisse GroupBoost Price TargetUnderperform$101.00 ➝ $120.00Low
i
7/29/2019Jefferies Financial GroupBoost Price TargetBuy$150.00 ➝ $167.00Low
i
7/29/2019Robert W. BairdUpgradeNeutral ➝ Outperform$132.00 ➝ $154.00Low
i
7/26/2019CowenSet Price TargetHold$140.00N/A
i
Rating by Josh Jennings at Cowen Inc
6/11/2019Sanford C. BernsteinUpgradeUnderperform ➝ Market Perform$121.71Low
i
4/26/2019Cantor FitzgeraldSet Price TargetBuy$135.00Low
i
Rating by Craig Bijou at Cantor Fitzgerald
4/24/2019Needham & Company LLCUpgradeBuy ➝ Strong-Buy$146.00 ➝ $155.00Low
i
4/15/2019BarclaysBoost Price TargetUnderweight ➝ Underweight$113.00 ➝ $117.00Low
i
Rating by Kristen Stewart at Barclays PLC
4/8/2019Evercore ISIUpgradeIn-Line ➝ Outperform$145.00Low
i
3/4/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$132.00 ➝ $143.00Low
i
2/5/2019BarclaysSet Price TargetSell$113.00Low
i
Rating by Kristen Stewart at Barclays PLC
2/5/2019SunTrust BanksBoost Price TargetBuy$135.00Low
i
2/2/2019OppenheimerReiterated RatingBuyLow
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
1/25/2019Cantor FitzgeraldSet Price TargetBuy$135.00Low
i
Rating by Craig Bijou at Cantor Fitzgerald
1/22/2019Stifel NicolausLower Price TargetBuy$150.00 ➝ $135.00Low
i
1/18/2019Cantor FitzgeraldSet Price TargetBuy$135.00Medium
i
Rating by Craig Bijou at Cantor Fitzgerald
1/15/2019Cantor FitzgeraldReiterated RatingOverweightN/A
i
Rating by C. Bijou at Cantor Fitzgerald
1/2/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold ➝ Hold$108.00Medium
i
1/2/2019Morgan StanleyLower Price TargetOverweight ➝ Overweight$149.00 ➝ $126.00Low
i
1/2/2019CitigroupUpgradeNeutral ➝ Buy$122.00 ➝ $127.00Low
i
12/19/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$140.00 ➝ $118.00Low
i
12/17/2018Credit Suisse GroupInitiated CoverageUnderperform$102.00Medium
i
12/6/2018OppenheimerSet Price TargetBuy$135.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
11/27/2018UBS GroupInitiated CoverageBuy ➝ Buy$140.00High
i
10/29/2018SVB LeerinkLower Price TargetOutperform$146.00 ➝ $141.00Low
i
10/29/2018Jefferies Financial GroupLower Price TargetBuy ➝ Buy$145.00 ➝ $140.00Low
i
10/29/2018CitigroupLower Price TargetNeutral ➝ Neutral$129.00 ➝ $122.00Medium
i
10/29/2018BarclaysLower Price TargetUnderweight ➝ Sell$131.00 ➝ $119.00Medium
i
Rating by Kristen Stewart at Barclays PLC
10/29/2018OppenheimerSet Price TargetBuy$135.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
10/28/2018BTIG ResearchReiterated RatingHoldLow
i
10/15/2018BarclaysInitiated CoverageUnderweight ➝ Underweight$131.00High
i
10/11/2018Morgan StanleyBoost Price TargetOverweight$140.00 ➝ $149.00High
i
8/27/2018OppenheimerReiterated RatingBuyLow
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/27/2018Needham & Company LLCReiterated RatingBuy$150.00High
i
8/27/2018Cantor FitzgeraldReiterated RatingBuy$150.00High
i
8/16/2018BTIG ResearchInitiated CoverageNeutralLow
i
8/13/2018Needham & Company LLCDowngradeStrong-Buy ➝ Buy$150.00Low
i
7/31/2018CitigroupBoost Price TargetNeutral ➝ Neutral$117.00 ➝ $128.00Low
i
7/30/2018Jefferies Financial GroupBoost Price TargetBuy$145.00Low
i
7/30/2018Piper Jaffray CompaniesBoost Price TargetNeutral$110.00 ➝ $120.00Low
i
7/30/2018Robert W. BairdBoost Price TargetNeutral ➝ Neutral$121.00 ➝ $132.00Low
i
7/30/2018Raymond JamesBoost Price TargetOutperform ➝ Outperform$135.00 ➝ $145.00Low
i
7/30/2018Needham & Company LLCBoost Price TargetStrong-Buy$146.00 ➝ $150.00Medium
i
7/30/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$140.00 ➝ $150.00Medium
i
7/30/2018JMP SecuritiesBoost Price TargetMarket Outperform ➝ Outperform$133.00 ➝ $140.00Medium
i
7/30/2018Canaccord GenuityBoost Price TargetHold ➝ Hold$122.00 ➝ $125.00Medium
i
7/27/2018OppenheimerReiterated RatingBuy$130.00 ➝ $138.00High
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
6/27/2018Sanford C. BernsteinInitiated CoverageUnderperform$96.00High
i
6/22/2018ArgusDowngradeBuy ➝ HoldHigh
i
4/27/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$148.00 ➝ $140.00Low
i
4/27/2018JMP SecuritiesLower Price TargetMarket Outperform ➝ Market Outperform$145.00 ➝ $133.00Low
i
4/27/2018Needham & Company LLCLower Price TargetStrong-Buy ➝ Strong-Buy$155.00 ➝ $146.00Medium
i
4/12/2018Canaccord GenuityReiterated RatingHold$121.00Low
i
4/2/2018Evercore ISIInitiated CoverageIn-Line$115.00Low
i
3/23/2018Robert W. BairdDowngradeOutperform ➝ NeutralHigh
i
3/15/2018OppenheimerInitiated CoverageOutperform$135.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
3/15/2018Raymond JamesInitiated CoverageOutperform$135.00Low
i
2/27/2018CitigroupLower Price TargetNeutral ➝ Neutral$132.00 ➝ $121.00Low
i
2/26/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$150.00 ➝ $148.00Low
i
2/5/2018Cantor FitzgeraldReiterated RatingBuy$140.00High
i
1/31/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$142.00 ➝ $146.00Low
i
1/31/2018Stifel NicolausUpgradeHold ➝ Buy$120.00 ➝ $168.00Low
i
1/31/2018Robert W. BairdReiterated RatingBuyLow
i
1/30/2018BMO Capital MarketsReiterated RatingBuy$144.00Low
i
1/30/2018Cantor FitzgeraldReiterated RatingBuy$140.00Low
i
1/30/2018Needham & Company LLCBoost Price TargetStrong-Buy ➝ Strong-Buy$144.00 ➝ $155.00Medium
i
1/29/2018SunTrust BanksBoost Price TargetBuy$142.00Medium
i
Rating by Bruce Nudell at SunTrust Banks, Inc.
1/29/2018Morgan StanleyBoost Price Target$140.00 ➝ $150.00Medium
i
1/5/2018Canaccord GenuityReiterated RatingHold$132.00Low
i
1/5/2018Cantor FitzgeraldReiterated RatingOverweight ➝ OverweightLow
i
Rating by Travis Steed at Cantor Fitzgerald
12/19/2017The Goldman Sachs GroupUpgradeSell ➝ Neutral$125.00Low
i
12/19/2017Canaccord GenuityReiterated RatingHold$125.00Low
i
12/19/2017OppenheimerReiterated RatingBuyMedium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
12/19/2017Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformLow
i
12/12/2017BMO Capital MarketsReiterated RatingBuy$142.00Low
i
11/14/2017Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$128.00N/A
i
Rating by Kristen Stewart at Deutsche Bank Aktiengesellschaft
11/9/2017Edward JonesUpgradeHold ➝ BuyN/A
i
11/7/2017Royal Bank of CanadaLower Price TargetOutperform$125.00N/A
i
11/3/2017Stifel NicolausReiterated RatingHold$120.00N/A
i
11/3/2017Jefferies Financial GroupReiterated RatingBuy$136.00N/A
i
11/2/2017Morgan StanleyLower Price TargetOverweight$146.00 ➝ $136.00N/A
i
11/2/2017BMO Capital MarketsLower Price TargetOutperform$140.00 ➝ $135.00N/A
i
11/2/2017Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralN/A
i
11/1/2017SunTrust BanksSet Price TargetBuy$136.00N/A
i
Rating by Bruce Nudell at SunTrust Banks, Inc.
10/2/2017SunTrust BanksReiterated RatingBuy$136.00Low
i
8/24/2017GabelliInitiated CoverageBuy$142.00Low
i
Rating by J. Tsai at Gabelli
8/14/2017OppenheimerSet Price TargetBuy$137.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
7/28/2017BMO Capital MarketsBoost Price TargetOutperform$136.00 ➝ $140.00Low
i
7/28/2017SVB LeerinkBoost Price TargetOutperform$141.00 ➝ $146.00Low
i
7/28/2017OppenheimerSet Price TargetBuy$137.00Medium
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
7/28/2017Piper Jaffray CompaniesReiterated RatingBuy$135.00Medium
i
7/28/2017Canaccord GenuityDowngradeBuy ➝ Hold$141.00 ➝ $135.00Medium
i
Rating by Kyle Rose at Canaccord Genuity
7/27/2017Cantor FitzgeraldSet Price TargetHold$137.00Low
i
Rating by Travis Steed at Cantor Fitzgerald
7/17/2017Morgan StanleyBoost Price TargetOverweight$137.00 ➝ $150.00Low
i
7/14/2017Piper Jaffray CompaniesReiterated RatingBuy$141.00Low
i
7/14/2017Stifel NicolausReiterated RatingHold$125.00Low
i
7/14/2017Bank of AmericaReiterated RatingBuy ➝ Buy$158.00Medium
i
7/14/2017Wells Fargo & CompanyReiterated RatingMarket WeightHigh
i
7/14/2017Royal Bank of CanadaReiterated RatingOutperform$140.00High
i
7/14/2017Canaccord GenuityReiterated RatingBuy$141.00High
i
Rating by Kyle Rose at Canaccord Genuity
7/12/2017Needham & Company LLCReiterated RatingStrong-Buy$153.00Low
i
7/12/2017GuggenheimUpgradeNeutral ➝ Buy$157.00Medium
i
7/11/2017BMO Capital MarketsReiterated RatingBuy$136.00Low
i
6/30/2017Jefferies Financial GroupReiterated RatingBuy$148.00Low
i
6/29/2017Cantor FitzgeraldInitiated CoverageNeutral ➝ Neutral$137.00Low
i
6/21/2017Royal Bank of CanadaBoost Price TargetOutperform$133.00 ➝ $140.00Medium
i
6/9/2017CitigroupBoost Price TargetNeutral$108.00 ➝ $130.00Low
i
5/16/2017The Goldman Sachs GroupInitiated CoverageSell ➝ Sell$92.00High
i
4/28/2017Canaccord GenuityReiterated RatingBuyLow
i
Rating by Kyle Rose at Canaccord Genuity
4/28/2017OppenheimerSet Price TargetBuy$132.00Low
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
4/28/2017Needham & Company LLCBoost Price TargetStrong-Buy ➝ Strong-Buy$151.00 ➝ $153.00Medium
i
4/28/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformMedium
i
3/14/2017Royal Bank of CanadaReiterated RatingBuy$133.00Medium
i
2/17/2017Needham & Company LLCReiterated RatingStrong-Buy$151.00N/A
i
2/1/2017OppenheimerSet Price TargetBuy$126.00 ➝ $132.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
2/1/2017Robert W. BairdReiterated RatingOutperform$130.00 ➝ $136.00N/A
i
2/1/2017Royal Bank of CanadaBoost Price TargetOutperform$130.00 ➝ $133.00N/A
i
Rating by glenn novarro at Royal Bank of Canada
1/31/2017Canaccord GenuitySet Price TargetBuy$144.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
1/25/2017Needham & Company LLCBoost Price TargetStrong-Buy$148.00 ➝ $151.00N/A
i
1/23/2017Canaccord GenuitySet Price TargetBuy$130.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
1/5/2017JPMorgan Chase & Co.Set Price TargetBuy$134.00N/A
i
Rating by Michael Weinstein at JPMorgan Chase & Co.
12/21/2016UBS GroupDowngradeNeutral ➝ Sell$113.00 ➝ $100.00N/A
i
12/15/2016UBS GroupDowngradeNeutral ➝ SellN/A
i
12/15/2016Needham & Company LLCReiterated RatingBuy$148.00N/A
i
Rating by Michael Matson at Needham & Company LLC
11/29/2016CitigroupUpgradeSell ➝ NeutralN/A
i
11/8/2016Northcoast ResearchDowngradeBuy ➝ NeutralN/A
i
Rating by D. Keiser at Northcoast Research
11/1/2016SVB LeerinkReiterated RatingOutperform$150.00 ➝ $136.00N/A
i
Rating by Richard Newitter at SVB Leerink LLC
11/1/2016Royal Bank of CanadaReiterated RatingOutperform$143.00 ➝ $130.00N/A
i
Rating by glenn novarro at Royal Bank of Canada
11/1/2016Royal Bank of CanadaLower Price TargetOutperform$143.00 ➝ $130.00N/A
i
Rating by Glenn Novarro at Royal Bank of Canada
11/1/2016Needham & Company LLCUpgradeBuy ➝ Strong-Buy$150.00 ➝ $148.00N/A
i
Rating by Michael Matson at Needham & Company LLC
11/1/2016Jefferies Financial GroupLower Price TargetBuy$150.00 ➝ $129.00N/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
10/31/2016Canaccord GenuityReiterated RatingBuy$150.00 ➝ $130.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
9/22/2016ArgusReiterated RatingBuy$140.00N/A
i
Rating by Upgraded, 2 days ago Buy at Argus
9/14/2016Royal Bank of CanadaSet Price TargetBuy$143.00N/A
i
Rating by glenn novarro at Royal Bank of Canada
8/23/2016BarclaysBoost Price TargetOverweight$140.00 ➝ $145.00N/A
i
Rating by Matthew Taylor at Barclays PLC
8/11/2016SunTrust BanksInitiated CoverageBuy$155.00N/A
i
8/10/2016SunTrust BanksInitiated CoverageBuyN/A
i
8/8/2016Jefferies Financial GroupReiterated RatingBuy$150.00N/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
8/2/2016UBS GroupReiterated RatingNeutral$117.00 ➝ $132.00N/A
i
Rating by Matt Miksic at UBS Group AG
7/29/2016BMO Capital MarketsReiterated RatingBuy$146.00N/A
i
7/29/2016JPMorgan Chase & Co.Boost Price TargetOverweight$134.00 ➝ $148.00N/A
i
7/29/2016JMP SecuritiesBoost Price TargetMarket Outperform$131.00 ➝ $145.00N/A
i
7/29/2016Jefferies Financial GroupBoost Price TargetBuy$135.00 ➝ $150.00N/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
7/29/2016CitigroupBoost Price TargetSell$91.00 ➝ $95.00N/A
i
7/29/2016BarclaysBoost Price TargetOverweight$135.00 ➝ $140.00N/A
i
Rating by Matthew Taylor at Barclays PLC
7/29/2016Needham & Company LLCBoost Price TargetBuy$143.00 ➝ $150.00N/A
i
Rating by Michael Matson at Needham & Company LLC
7/18/2016Needham & Company LLCReiterated RatingBuy$134.00 ➝ $143.00N/A
i
Rating by Michael Matson at Needham & Company LLC
6/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$125.00N/A
i
6/8/2016Needham & Company LLCReiterated RatingBuyN/A
i
Rating by Michael Matson at Needham & Company LLC
6/8/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by Kyle Rose at Canaccord Genuity
6/8/2016UBS GroupReiterated RatingHoldN/A
i
Rating by Matt Miksic at UBS Group AG
6/8/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Richard Newitter at SVB Leerink LLC
6/8/2016Morgan StanleyReiterated RatingBuyN/A
i
Rating by David Lewis at Morgan Stanley
6/8/2016GuggenheimInitiated CoverageNeutralN/A
i
6/8/2016Royal Bank of CanadaReiterated RatingBuy$132.00N/A
i
6/8/2016Jefferies Financial GroupReiterated RatingBuy$135.00N/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
5/25/2016ArgusUpgradeHold ➝ Buy$140.00N/A
i
5/22/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
5/16/2016Sterne Agee CRTReiterated RatingBuyN/A
i
Rating by G. Chodaczek at Sterne Agee CRT
5/2/2016SVB LeerinkBoost Price TargetOutperform$124.00 ➝ $135.00N/A
i
4/30/2016OppenheimerReiterated RatingBuyN/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
4/30/2016Morgan StanleyReiterated RatingBuyN/A
i
Rating by David Lewis at Morgan Stanley
4/30/2016BarclaysReiterated RatingBuyN/A
i
Rating by Matthew Taylor at Barclays PLC
4/29/2016UBS GroupReiterated RatingHold$117.00N/A
i
4/29/2016BarclaysBoost Price TargetOverweight$130.00 ➝ $135.00N/A
i
4/28/2016Canaccord GenuityReiterated RatingBuy$150.00N/A
i
4/28/2016Needham & Company LLCReiterated RatingBuy$129.00 ➝ $134.00N/A
i
Rating by Michael Matson at Needham & Company LLC
4/15/2016Royal Bank of CanadaBoost Price TargetOutperform$120.00 ➝ $132.00N/A
i
4/11/2016OppenheimerReiterated RatingOutperform$120.00N/A
i
Rating by Steven Lichtman at Oppenheimer Holdings Inc.
4/8/2016The Goldman Sachs GroupLower Price Target$113.00 ➝ $111.00N/A
i
3/24/2016Jefferies Financial GroupReiterated RatingBuy$129.00N/A
i
Rating by Raj Denhoy at Jefferies Financial Group Inc.
3/20/2016Bank of AmericaInitiated CoverageBuy$127.00N/A
i
Rating by Ed Ridley-Day at Bank of America Co.
3/17/2016Nomura SecuritiesInitiated CoverageBuy$123.00N/A
i
3/11/2016Jefferies Financial GroupReiterated RatingBuy$125.00 ➝ $129.00N/A
i
3/4/2016ArgusDowngradeBuy ➝ HoldN/A
i
2/16/2016Piper Jaffray CompaniesReiterated RatingOverweight$125.00N/A
i
2/8/2016OppenheimerReiterated RatingOutperform$124.00 ➝ $120.00N/A
i
1/31/2016Canaccord GenuityReiterated RatingBuy$150.00N/A
i
Rating by William Plovanic at Canaccord Genuity
1/31/2016William BlairReiterated RatingOutperformN/A
i
Rating by K. Krum at William Blair
1/29/2016Northland SecuritiesLower Price Target$109.00 ➝ $105.00N/A
i
1/29/2016SVB LeerinkLower Price TargetOutperform$124.00N/A
i
1/29/2016Needham & Company LLCReiterated RatingBuy$127.00 ➝ $129.00N/A
i
1/27/2016JMP SecuritiesBoost Price TargetMarket Outperform$118.00 ➝ $125.00N/A
i
1/7/2016Northland SecuritiesDowngradeOutperform ➝ Market Perform$130.00 ➝ $109.00N/A
i
12/3/2015Royal Bank of CanadaReiterated RatingOutperform$136.00 ➝ $125.00N/A
i
12/3/2015Deutsche Bank AktiengesellschaftReiterated RatingHold$107.00 ➝ $114.00N/A
i
(Data available from 11/29/2015 forward)
Zimmer Biomet logo
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and office based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Read More

Today's Range

Now: $150.02
$148.57
$150.63

50 Day Range

MA: $144.11
$132.10
$155.95

52 Week Range

Now: $150.02
$74.37
$165.15

Volume

381,674 shs

Average Volume

1,428,076 shs

Market Capitalization

$31.10 billion

P/E Ratio

937.68

Dividend Yield

0.64%

Beta

1.34